Lung cancer therapy using an engineered respiratory syncytial virus
OwnerWeidong Zhang, Lixian Jiang +1inventors
InventorsWeidong Zhang, Lixian Jiang, Calvin Cao
Life of this patent
Estimating the term…
Abstract
The invention discloses an engineered oncolytic respiratory syncytial virus (RSV), NS1 gene deficient RSV, and its usage to treat lung cancer by killing cancer cells with in vitro and in vivo evidences.
Claims3
A method to treat lung cancer in a subject in need thereof, comprising 1) administering in a liquid medium to the neoplasm of a subject an engineered respiratory syncytial virus (RSV) with the NS1 gene deleted, wherein the RSV infects and causes oncolysis, thereby treating the neoplasm in the subject.
A method to treat lung cancer in a subject in need thereof, comprising 1) administering to the neoplasm of a subject an engineered respiratory syncytial virus (RSV) with the NS1 gene deleted, wherein the RSV is suspended in saline, and wherein the RSV infects and causes oncolysis thereby treating the neoplasm in the subject.
Dependencies are inferred from the claim text.